Company Overview
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Recent Developments
- Jun 2025 Revenue of $400.00K (+77.8% YoY); net profit $-18.38M.
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -8.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -8.54% |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +78.08% |
| 6 Months: | -48.00% |
| 3 Months: | -24.86% |
| 1 Month: | -7.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -8.5% CAGR over 5 years.
- Trading 57.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IBIO iBio, Inc. PHARMA | 1.30 | -4.06 | $64.58M | 0.00% | -108.92% | -65.70% | -8.54% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 50.00K | - | - | 0 | 200.00K | 0 | 100.00K | 0 | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00K | 303.00K | 494.00K | 272.00K | 171.00K | 55.00K | 1.90M | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.86M | 240.00K | -1.64M | -1.29M | -1.42M | -1.67M | -1.69M | -1.81M | -2.25M | -3.07M | -3.15M | -3.33M | -3.94M | -3.36M | -3.43M | -3.49M | -3.95M | -4.01M | -3.77M | -3.85M | -3.15M | -4.06M | -6.92M | -7.54M | -7.20M | -5.22M | -7.23M | -6.79M | -7.64M | -10.57M | -6.17M | -5.10M | -4.50M | -3.63M | -4.11M | -4.42M | -4.88M | -5.95M | -9.45M | -8.37M |
| Net Income | -1.76M | 379.00K | -1.62M | -1.28M | -1.41M | -1.65M | -1.68M | -1.80M | -2.25M | -3.04M | -3.06M | -3.23M | -3.91M | -3.83M | -3.90M | -3.96M | -4.40M | -4.47M | -4.22M | -4.46M | -3.76M | -4.68M | -7.53M | -8.13M | -7.66M | -8.94M | -11.92M | -12.39M | -18.13M | -33.55M | -7.29M | -5.75M | -8.21M | -3.17M | -3.99M | -4.36M | -4.86M | -5.72M | -8.99M | -7.73M |
| Diluted EPS | - | 0.01 | - | - | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.04 | -3.82 | -1.37 | -1.42 | -2.05 | -68.43 | -11.07 | -4.80 | -4.42 | -0.85 | -0.46 | -0.48 | -0.49 | -0.11 | -0.09 | -0.06 |
| R&D Expense | 631.00K | 552.00K | 585.00K | 343.00K | 1.19M | 731.00K | 815.00K | 551.00K | 704.00K | 1.05M | 820.00K | 1.05M | 1.14M | 985.00K | 993.00K | 966.00K | 1.12M | 1.27M | 1.45M | 977.00K | 888.00K | 1.09M | 1.86M | 2.37M | 2.16M | 1.13M | 1.86M | 3.27M | 2.55M | 2.78M | 2.64M | 1.61M | 1.53M | 904.00K | 1.30M | 1.88M | 1.91M | 3.55M | 4.28M | 3.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.28M | 1.01M | 205.00K | 1.85M | 948.00K | 394.00K | 444.00K | 2.02M | 1.64M | 2.37M | 1.88M | 0 | 225.00K | 400.00K |
| Gross Profit | - | - | - | - | - | - | - | - | 935.00K | 909.00K | 2.17M | - | - | - |
| Operating Income | -9.33M | -6.67M | -3.84M | -6.67M | -9.89M | -14.27M | -14.23M | -15.79M | -14.00M | -31.11M | -29.70M | -29.34M | -16.63M | -18.60M |
| Net Income | -5.68M | -6.20M | -3.67M | -6.62M | -9.76M | -14.53M | -16.11M | -17.59M | -16.44M | -23.21M | -50.30M | -65.01M | -24.91M | -18.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -3.00 | -5.78 | -106.19 | -6.50 | -1.75 |
| R&D Expense | 4.98M | 3.43M | 1.90M | 3.50M | 3.16M | 4.12M | 3.99M | 5.47M | 3.57M | 9.99M | 9.83M | 10.33M | 5.18M | 8.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Mar 2018 | Jun 2018 | Jun 2019 | Mar 2020 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.77M | 9.35M | 6.49M | 12.49M | 51.60M | 36.01M | - | 43.08M | 30.59M | 42.22M | 94.19M | 146.97M | 99.41M | 41.21M | 28.73M | 23.18M |
| Total Equity | 196.00K | 6.17M | 5.07M | 6.10M | 11.23M | 9.94M | 8.91M | 4.20M | 16.17M | 2.46M | 3.96M | 56.62M | 108.58M | 63.48M | 15.38M | 21.32M | 14.88M |
| Cash & Equivalents | 2.84M | 5.62M | 4.41M | 3.59M | 9.49M | 15.93M | 15.93M | - | 4.42M | 4.42M | - | 55.11M | 77.40M | 22.68M | 4.30M | 14.21M | 8.58M |
| Total Liabilities | - | - | - | 395.00K | 1.26M | 27.56M | 27.09M | - | 26.92M | 28.13M | - | 37.58M | 38.40M | 35.92M | 25.83M | 7.41M | 8.30M |
| Current Liabilities | - | 3.60M | 4.29M | 395.00K | 1.26M | 2.29M | 2.01M | - | 2.04M | 3.46M | - | 5.24M | 6.64M | 30.44M | 22.11M | 3.84M | 6.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.01M | -4.85M | - | - | - | -13.16M | -13.48M | -13.97M | -13.35M | -30.06M | -37.48M | -30.44M | -18.55M | -15.30M |
| Investing Cash Flow | -245.00K | -195.00K | - | - | - | -1.59M | -1.08M | -990.00K | -1.15M | -26.48M | -5.13M | 7.01M | 906.00K | 742.00K |
| Financing Cash Flow | 9.04M | 3.83M | - | - | - | -170.00K | 22.41M | 3.45M | 65.19M | 78.83M | -6.12M | 2.30M | 24.49M | 8.93M |
| Capital Expenditure | -1.00K | -7.00K | -4.00K | -13.00K | -68.00K | -1.32M | -934.00K | -920.00K | -1.08M | -4.92M | -7.33M | -5.74M | -210.00K | -16.00K |
| Free Cash Flow | -6.01M | -4.86M | - | - | - | -14.49M | -14.41M | -14.89M | -14.42M | -34.98M | -44.81M | -36.17M | -18.76M | -15.32M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 57.1% | 38.3% | 115.0% | - | - | - |
| Operating Margin % | -730.4% | -662.1% | -1,873.2% | -360.1% | -1,043.6% | -3,622.8% | -3,204.3% | -782.4% | -854.9% | -1,312.1% | -1,576.3% | - | -7,392.9% | -4,650.5% |
| Net Margin % | -444.5% | -615.5% | -1,788.3% | -357.9% | -1,030.0% | -3,688.3% | -3,627.3% | -871.8% | -1,003.6% | -978.8% | -2,670.0% | - | -11,069.8% | -4,594.2% |
| ROE % | -92.0% | -122.3% | -60.1% | -59.0% | -98.3% | -163.0% | -99.6% | -714.3% | -29.0% | -21.4% | -79.2% | -422.7% | -116.8% | -123.5% |
| ROCE % | -151.2% | -131.6% | -63.0% | -59.4% | -20.1% | -42.0% | -34.7% | -58.2% | -15.7% | -22.2% | -43.1% | -153.6% | -66.8% | -108.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Affinity Asset Advisors, Llc | 6.23% | 4.01M | $5.13M |
| 2 | Cormorant Asset Management, LP | 5.55% | 3.57M | $4.57M |
| 3 | SilverArc Capital Management, LLC | 5.47% | 3.52M | $4.51M |
| 4 | Vestal Point Capital, LP | 4.04% | 2.60M | $3.33M |
| 5 | Vanguard Capital Management LLC | 3.26% | 2.10M | $2.69M |
| 6 | Frazier Life Sciences Management, L.P. | 3.04% | 1.95M | $2.50M |
| 7 | Ensign Peak Advisors, Inc | 2.85% | 1.83M | $2.35M |
| 8 | Woodline Partners LP | 2.76% | 1.78M | $2.27M |
| 9 | Millennium Management Llc | 2.57% | 1.65M | $2.11M |
| 10 | Citadel Advisors Llc | 2.15% | 1.38M | $1.77M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IBIO
iBio, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQYlVveWl5V2VmcGZhdzU4MXJWOWo0aWd6ekx1bkhBZmMzUDl3VU96YWgxZUZRdC1XU1VmWlB5Vy1lWUdDY2p5S0FpVzh0Z19wNmN5b3JXZzVJNkpsQjVqbmlPSmlmdzVscXZEYUZxVjdiLW9lQjJrNEVqcmJwUURPVFBVRENLVFQ1QVNZbm…
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQQjRhaU5HTjJKZmRLQjZvX3c3MlhyWkYxb1Z1ZGtEOTNyaHlXSlpCX1JZdFZMX1J5WWR5eWJGUk5GeldrbFYzNzkzZ2pWalRCeXlvVlBJc3FuN2hNQ0ZNYjhyWkJ1eVVMd0V1UEVSYnNRUkZwMUVDbG9QX0F4cVIxR3NhRXYzeVQtZlBqSW…
iBio (NASDAQ: IBIO) Shareholders Set to Vote on 500 Million Share Increase on October 14, 2026 - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOdm5TdXZGSEUySGdkTHYyT181dElrSFVlU0hDclVVdGF3TmxtM0Zlb2ctT2RNd0tzaTdycW9ySlBYbFFhOWNyeTNHMWpYVWkxS3FISk1sRHN2X3lwWjlaVl9TbDRnX3JHeVhJZFVyMVFheW55MXdnYUJtaW1HY2JpZEhKRTF0YTZ0Q0pFUG…
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSjlwLU9yMWtvZllsd0IxV2Y3emtUVHZMdERoQmVtRnBnX09ocEV5aG9hVkxvYUk1bGVUTzN5V1kwckVRWGZKSkdYdWNwTHNfVzRyZmFlVVdmMzBXR0ZFaHE2dU5fSFFyUXZScVZVc0pEQ2VZZzhoUXFYS25FREZrMktkRHVsWi15Ym4xb0…
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNYnIwNFVTZlVSSXFXdFhzOHI5OVI3Z2hleU8tLTlScXdLTzZ5RFI3ejBrQk5PNWdrVGVhcTQ2T1RoQnRzcUh6VTljMWN6NmFRTHpZZ3hwSmM2eVo0QWJ4UFBLdlE5YVp1ZWRTeTh5cVhGV3NYZUZFeDB5eWxhZWxfdDl3dkVHd2xzZ2NVR2…
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPS1I5N0lRNmEtR2hpRXQ0cFkyclNKaWloZm1pdXZEZDRycmV6T18yZjFialJuS1pEQWp5bU1FWWlYZmxZMXpROFFaWkswaVZhWmpEeGdzaFpJUEYzZTEtTTdnbHAwdXNaTUZIaXZJRW9DQl9RLURZUV9GZklmTWQ3Ujd1UWFodFNMWEczRk…
IBIO — Frequently Asked Questions
What is the current share price of iBio, Inc. (IBIO)?
As of 2026-09-19 21:16 PDT, iBio, Inc. (IBIO) trades at $1.30 on NasdaqCM. Its 52-week range is $0.68 to $3.07.
What is the market capitalisation of IBIO?
iBio, Inc. (IBIO) has a market capitalisation of $64.58M on NasdaqCM.
What is the P/E ratio of IBIO?
IBIO trades at a trailing price-to-earnings (P/E) ratio of -4.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.83.
What is the return on equity (ROE) of IBIO?
IBIO has a return on equity (ROE) of -65.70%. Its return on capital employed (ROCE) is -108.92%.
Is IBIO a good stock to buy?
This page provides a data-driven analysis of iBio, Inc. (IBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.